Repros Therapeutics Inc. Confirms Guidance On Ongoing Clinical Studies; Proellex Uterine Fibroid Study Reaches Full Recruitment; Company Intends To File Shelf Registration

THE WOODLANDS, Texas--(BUSINESS WIRE)--Sept. 5, 2006--Repros Therapeutics Inc. (Nasdaq:RPRX) (PCX:RPRX) today provided an update regarding the progress of its three ongoing clinical studies. The studies include a 200 patient U.S. Phase 3 study of Androxal(TM) for the treatment of testosterone deficiency in men with secondary hypogonadism, a 150 patient U.S. Phase 2 study of Proellex(TM) in the treatment of uterine fibroids and a 40 patient European Phase 2 study of Proellex(TM) in the treatment of endometriosis.